NEW YORK (GenomeWeb News) – Response Genetics today reported that its revenues for the fourth quarter increased 12 percent year over year on the strength of its pharmaceutical client business.

The Los Angeles-based molecular diagnostic firm posted $5.5 million in revenues for the three months ended Dec. 31, 2012, compared to $4.9 million a year ago. Pharmaceutical client revenues rose 36 percent year over year, the company said, while revenues generated from Response DX genetic tests slid 1 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.